MBP and myeloid sarcoma: As a proof of concept of the presence of higher levels of pU24-6A and pU24-6B in MS patients, we evaluated the titration of plasma IgG towards MBP and U24 peptides listed in Table 1, in 40 MS patients, 40 control subjects (CTR) and 40 neurolupus (NLES) patients.